Menu

Pharma News

05 AA011027

Amgen’s approach in the biosimilars market

Home/Pharma News | Posted 23/01/2015

Biotech giant Amgen now has a biosimilars programme that includes nine different molecules [1]. A representative from Amgen has spoken to GaBI about the company’s venture into biosimilars [2].

2014 shutterstock 233120428

Top 10 most read GaBI Online articles in 2014

Home/Pharma News | Posted 16/01/2015

2014 was once again a busy year for biosimilars, ranging from revision of regulatory guidelines to naming and extrapolation. Biosimilars remain the hot topic for GaBI Online during 2014 and, in fact, all 10 of the most read articles concern biosimilars.

picture 149

Cipla makes deal with Serum Institute for vaccines in Europe

Home/Pharma News | Posted 05/12/2014

India-based generics maker Cipla announced on 20 November 2014 that it had signed a deal with the Serum Institute of India (Serum Institute) to distribute vaccines in Europe.

Business Aquisition V13F07

Actavis buys Allergan and joins pharma top 10

Home/Pharma News | Posted 28/11/2014

On 17 November 2014, US generics maker Actavis announced that the company had made a deal to acquire botox-maker Allergan for US$66 billion.

Shaking hands V13D29

Xbrane signs biosimilar optimization deal with Indian pharma firm

Home/Pharma News | Posted 14/11/2014

Swedish biotech company Xbrane Bioscience (Xbrane) has signed an agreement with a global Indian pharmaceutical company to assist them in developing an optimized production system for a specific biosimilar that will be marketed worldwide. The aim is to help the client reduce production costs in order to gain a competitive advantage in the biosimilar market.

South Africa V13K08

Cipla Medpro to collaborate with Teva for generics in South Africa

Home/Pharma News | Posted 07/11/2014

India-based generics maker Cipla announced on 8 October 2014 that it had made a collaboration deal with Israel’s Teva Pharmaceuticals for sales and distribution of the latter’s generic drugs in South Africa.

27 MD002442

Supernus sues Actavis over generic Trokendi XR

Home/Pharma News | Posted 31/10/2014

US-based central nervous system specialist Supernus Pharmaceuticals (Supernus) announced on 2 Oct 2014 that it had sued generics maker Actavis for infringement of three patents covering its antiepileptic drug Trokendi XR (extended release topiramate). The three US patents (8,298,576, 8,298,580, and 8,663,683) cover once-a-day topiramate formulations and methods of treating seizures using those formulations.

picture 74

Generics maker IGI Labs gains rights to AstraZeneca injectables

Home/Pharma News | Posted 17/10/2014

Speciality topical generics maker IGI Laboratories (IGI Labs) announced on 25 September 2014 that it had acquired the rights for 18 drugs from AstraZeneca.

26 AA011066

India suffers HIV drug shortages

Home/Pharma News | Posted 10/10/2014

Supply bottlenecks and late payments to drugmakers have hit HIV treatment supplies across India, according to reports in the Indian press. The drug shortages, which affect those least able to pay, have seen some government distribution centres running out of drugs altogether.

Shaking hands V13D29

Biocad to be taken over by Russian investment firm

Home/Pharma News | Posted 02/06/2014

Russia’s biggest drugmaker, Pharmstandard, and investment company, Millhouse LLC, have said that they are planning to buy 70% of Russian biosimilars developer Biocad.